Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

DNA Analysis Software

February 8, 2011 7:26 am | Product Releases | Comments

QIAGEN has launched ScreenGel software for convenient DNA fragment and RNA analysis with the QIAxcel multicapillary gel electrophoresis systems. The software combines flexibility for researchers with standardized and reproducible operations in the lab.


Molecular Profiles Buys Microdoser

February 8, 2011 7:18 am | News | Comments

Molecular Profiles, a leading pharmaceutical development service provider, announces the continued expansion of its manufacturing capabilities with the recent purchase of the Xcelodose 120S system.


Thermo Fisher Collaborating With MGH/Harvard

February 8, 2011 7:15 am | News | Comments

Thermo Fisher Scientific Inc. announced the initial findings of stroke research conducted by its Biomarker Research Initiatives in Mass Spectrometry Center in collaboration with Massachusetts General Hospital, Harvard University.


Potential New Target for Antidepressants

February 8, 2011 7:05 am | News | Comments

Using a relatively simple cell-based fluorescent assay they developed, scientists have identified a means by which fluoxetine, the active ingredient in Prozac, suppresses the activity of the TREK1 potassium channel.


Protein May Lead to Pediatric Cancer Treatment

February 8, 2011 6:59 am | News | Comments

After analyzing hundreds of proteins produced by the DNA of tumor cells, researchers have identified one protein that may be central to a new treatment for the often-fatal childhood cancer neuroblastoma.


Rib-X Begins Phase 2 ABSSSI Trial

February 8, 2011 6:54 am | News | Comments

Rib-X Pharmaceuticals, Inc. initiated a Phase 2b clinical trial to evaluate delafloxacin, linezolid, and vancomycin for the treatment of acute bacterial skin and skin structure infections, including infections caused by methicillin-resistant Staphylococcus aureus.


Avastin Meets PFS Endpoint in Ovarian Cancer Trial

February 8, 2011 6:43 am | News | Comments

Genentech announced that OCEANS, a Phase 3 study evaluating Avastin in combination with chemotherapy followed by continued use of Avastin alone until disease progression in women with recurrent, platinum-sensitive ovarian cancer, met its primary endpoint.


New Imager to Aid Medical Research

February 8, 2011 6:39 am | News | Comments

Purdue University's Bindley Bioscience Center has installed a high-end imaging instrument to advance research in the areas of cancer, neuroscience, and cardiovascular and musculoskeletal diseases.


Natco Challenging Tamiflu Patent

February 8, 2011 6:35 am | News | Comments

Gilead Sciences Inc. said that Natco Pharma Ltd. is challenging a patent on the flu drug Tamiflu. Tamiflu was developed by Gilead, which receives royalties on the drug's sale from Roche Holding AG.


New Database Brings Researchers And Funds Together

February 8, 2011 6:33 am | News | Comments

In 2010, the National Institutes of Health was able to fund fewer than 25 percent of the research grant applications submitted to its 27 institutes and centers. In 2011, the National Health Council is giving unfunded NIH applications the potential for a new lease on life.


King Pharma Delisting Stock

February 8, 2011 6:27 am | News | Comments

King Pharmaceuticals Inc. said it plans to voluntarily delist its stock from the New York Stock Exchange as it completes its sale to Pfizer Inc. The company said its stock will be listed through Feb. 28.


IU Launches Personalized Medicine Institute

February 8, 2011 6:25 am | News | Comments

Indiana University has announced a major commitment to research in one of health care's most promising fields with the creation of the Indiana Institute for Personalized Medicine.


Pharmasset Reports Higher Than Expected Losses

February 8, 2011 6:21 am | News | Comments

Clinical-stage drugmaker Pharmasset Inc. reported a wider fiscal first-quarter loss Monday on higher research and development costs. The company lost $23.5 million, compared with a loss of $13.9 million the same quarter a year prior.


GSK Adds Safety Restrictions to Avandia Label

February 8, 2011 6:18 am | by Matthew Perrone | News | Comments

GlaxoSmithKline PLC said it has updated the labeling of its diabetes pill Avandia to include safety restrictions ordered by federal health authorities because of the drug's links to heart attack.


Danaher Acquiring Beckman Coulter for $6.8B

February 7, 2011 9:04 am | News | Comments

Beckman Coulter, Inc. announced that it has entered into a definitive merger agreement under which Danaher will acquire all of Beckman Coulter's outstanding common stock for $83.50 per share in cash.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.